Shionogi & Co., Ltd. (SGIOY) Income Statement Analysis

See more : Asia Fiber Public Company Limited (AFC.BK) Income Statement Analysis – Financial Results

Complete financial analysis of Shionogi & Co., Ltd. (SGIOY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shionogi & Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Shionogi & Co., Ltd. (SGIOY)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.shionogi.com

About Shionogi & Co., Ltd.

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998
Revenue	435.08B	426.68B	335.14B	297.18B	333.37B	367.96B	344.67B	338.89B	309.97B	273.99B	289.72B	282.90B	267.28B	282.35B	278.50B	227.51B	214.27B	199.76B	196.39B	199.37B	200.49B	285.23B	420.19B	412.66B	400.28B	372.17B	348.75B
Cost of Revenue	57.60B	70.10B	62.73B	59.18B	63.25B	62.25B	73.91B	77.78B	74.76B	82.19B	77.99B	78.57B	77.75B	81.74B	76.26B	70.93B	68.59B	67.54B	68.71B	74.07B	79.86B	153.40B	273.69B	263.63B	253.20B	232.45B	213.37B
Gross Profit	377.48B	356.58B	272.41B	238.00B	270.12B	305.71B	270.76B	261.11B	235.22B	191.80B	211.72B	204.33B	189.52B	200.61B	202.24B	156.58B	145.67B	132.22B	127.68B	125.30B	120.63B	131.83B	146.50B	149.04B	147.08B	139.72B	135.38B
Gross Profit Ratio	86.76%	83.57%	81.28%	80.09%	81.03%	83.08%	78.56%	77.05%	75.88%	70.00%	73.08%	72.23%	70.91%	71.05%	72.62%	68.82%	67.99%	66.19%	65.01%	62.85%	60.17%	46.22%	34.86%	36.12%	36.74%	37.54%	38.82%
Research & Development	102.64B	102.39B	73.00B	54.25B	47.95B	52.06B	59.95B	59.91B	49.79B	48.87B	51.92B	53.02B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	99.65B	97.78B	91.77B	91.90B	95.09B	87.67B	80.78B	78.18B	75.99B	75.65B	80.06B	77.79B	0.00	0.00	0.00	0.00	105.28B	103.35B	98.46B	96.57B	100.34B	112.56B	130.31B	125.13B	121.66B	116.81B	114.15B
Selling & Marketing	0.00	7.52B	9.98B	13.04B	15.41B	16.76B	14.81B	14.85B	18.03B	16.91B	16.18B	14.67B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	99.65B	93.64B	87.94B	88.06B	91.56B	85.29B	95.59B	93.03B	94.02B	92.57B	96.24B	92.46B	0.00	0.00	0.00	0.00	105.28B	103.35B	98.46B	96.57B	100.34B	112.56B	130.31B	125.13B	121.66B	116.81B	114.15B
Other Expenses	21.88B	0.00	0.00	0.00	-1.30B	-1.13B	-1.14B	-1.16B	-786.00M	-2.20B	-876.00M	-2.25B	-884.00M	-1.92B	-725.00M	-381.00M	-1.78B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	224.17B	196.03B	160.93B	142.31B	139.51B	137.34B	155.54B	152.93B	143.81B	141.44B	149.85B	144.76B	142.52B	153.72B	149.80B	124.57B	105.28B	103.35B	98.46B	96.57B	100.34B	112.56B	130.31B	125.13B	121.66B	116.81B	114.15B
Cost & Expenses	281.77B	266.13B	223.66B	201.48B	202.76B	199.59B	229.45B	230.71B	218.57B	223.63B	227.84B	223.34B	220.27B	235.46B	226.06B	195.50B	173.87B	170.90B	167.16B	170.64B	180.19B	265.97B	404.00B	388.76B	374.86B	349.26B	327.52B
Interest Income	51.67B	6.55B	779.00M	1.16B	2.78B	29.93B	1.17B	808.00M	774.00M	500.00M	376.00M	381.00M	384.00M	459.00M	484.00M	1.07B	1.35B	0.00	1.26B	1.07B	1.22B	1.19B	1.09B	0.00	0.00	0.00	0.00
Interest Expense	6.70B	1.92B	841.00M	941.00M	1.92B	1.95B	557.00M	220.00M	207.00M	274.00M	888.00M	1.12B	1.33B	1.48B	1.68B	701.00M	83.00M	96.00M	128.00M	443.00M	494.00M	570.00M	737.00M	786.00M	770.00M	1.39B	742.00M
Depreciation & Amortization	18.32B	17.17B	16.29B	14.71B	14.04B	18.70B	19.01B	16.34B	15.87B	15.65B	15.63B	15.12B	19.71B	22.36B	21.78B	14.37B	10.67B	8.80B	8.65B	9.41B	9.71B	10.19B	9.81B	9.27B	9.75B	8.55B	8.42B
EBITDA	186.70B	177.72B	127.77B	110.40B	144.65B	191.88B	156.94B	124.52B	107.28B	97.98B	79.70B	74.54B	67.46B	69.25B	73.97B	47.08B	51.67B	37.85B	47.58B	41.51B	31.22B	30.64B	29.31B	33.17B	38.21B	31.46B	29.65B
EBITDA Ratio	42.91%	41.65%	38.13%	37.15%	43.39%	50.84%	38.94%	36.74%	34.61%	34.46%	27.73%	26.82%	25.24%	24.53%	26.56%	20.69%	24.11%	18.95%	21.48%	19.67%	15.57%	10.74%	6.45%	8.04%	9.39%	8.45%	8.50%
Operating Income	153.31B	160.55B	111.48B	95.69B	130.61B	168.37B	115.22B	108.18B	91.41B	50.37B	61.88B	59.57B	47.00B	46.89B	52.44B	32.01B	40.40B	28.86B	29.23B	28.73B	20.29B	19.27B	16.18B	23.91B	25.42B	22.91B	21.23B
Operating Income Ratio	35.24%	37.63%	33.26%	32.20%	39.18%	45.76%	33.43%	31.92%	29.49%	18.38%	21.36%	21.05%	17.59%	16.61%	18.83%	14.07%	18.85%	14.45%	14.88%	14.41%	10.12%	6.75%	3.85%	5.79%	6.35%	6.16%	6.09%
Total Other Income/Expenses	44.97B	71.36B	15.98B	25.58B	27.89B	5.67B	22.16B	14.52B	6.05B	31.69B	2.99B	-1.26B	-5.51B	-13.76B	6.10B	-1.23B	-437.00M	2.86B	9.57B	2.93B	-15.11B	-10.13B	2.57B	647.00M	2.28B	1.06B	2.71B
Income Before Tax	198.28B	220.37B	126.29B	143.02B	158.52B	174.04B	137.38B	122.70B	97.45B	82.05B	63.19B	58.31B	41.49B	33.14B	58.54B	30.79B	39.96B	31.72B	38.80B	31.66B	5.18B	9.14B	18.76B	24.56B	27.70B	23.97B	23.94B
Income Before Tax Ratio	45.57%	51.65%	37.68%	48.13%	47.55%	47.30%	39.86%	36.20%	31.44%	29.95%	21.81%	20.61%	15.52%	11.74%	21.02%	13.53%	18.65%	15.88%	19.76%	15.88%	2.58%	3.20%	4.46%	5.95%	6.92%	6.44%	6.86%
Income Tax Expense	37.71B	35.84B	12.83B	30.96B	36.32B	37.12B	28.59B	39.08B	30.82B	37.83B	22.47B	-8.53B	14.39B	13.08B	19.90B	15.09B	14.87B	13.09B	16.03B	12.70B	2.95B	3.36B	10.66B	12.14B	14.96B	14.30B	14.43B
Net Income	162.03B	184.97B	114.19B	111.86B	122.19B	137.19B	108.87B	83.88B	66.69B	44.06B	40.62B	66.73B	27.10B	20.03B	38.63B	15.66B	25.06B	18.60B	22.74B	18.94B	2.20B	5.90B	8.46B	12.61B	12.87B	9.81B	9.57B
Net Income Ratio	37.24%	43.35%	34.07%	37.64%	36.65%	37.28%	31.59%	24.75%	21.51%	16.08%	14.02%	23.59%	10.14%	7.09%	13.87%	6.88%	11.70%	9.31%	11.58%	9.50%	1.10%	2.07%	2.01%	3.06%	3.21%	2.64%	2.74%
EPS	558.32	621.31	378.75	365.02	395.71	438.47	342.71	259.87	204.83	33.17	30.32	49.81	20.23	14.95	28.83	17.81	18.55	13.65	16.68	13.72	1.59	4.24	6.26	9.34	9.52	7.26	7.08
EPS Diluted	558.32	621.09	378.62	364.89	395.28	434.73	337.47	255.87	201.70	33.01	30.31	49.79	20.23	14.95	28.83	17.81	18.55	13.65	16.68	13.72	1.59	4.24	6.11	9.12	9.30	7.09	6.92
Weighted Avg Shares Out	290.21M	297.70M	301.48M	306.44M	308.80M	312.88M	317.66M	322.77M	325.58M	1.33B	1.34B	1.34B	1.34B	1.34B	1.34B	1.34B	1.35B	1.36B	1.36B	1.38B	1.38B	1.39B	1.35B	1.35B	1.35B	1.35B	1.35B
Weighted Avg Shares Out (Dil)	290.21M	297.81M	301.58M	306.55M	309.13M	315.58M	322.60M	327.77M	330.57M	1.33B	1.34B	1.34B	1.34B	1.34B	1.34B	1.34B	1.35B	1.36B	1.36B	1.38B	1.38B	1.39B	1.38B	1.38B	1.38B	1.38B	1.38B

Shionogi & Co., Ltd. (SGIOY) Q2 2024 Earnings Call Transcript

October 29, 2024seekingalpha.com

Shionogi & Co., Ltd. (OTCPK:SGIOY) Q2 2024 Earnings Call Transcript October 29, 2024 2:00 AM ET Company Participants Yoshimasa Kyokawa - Vice President, Corporate Communications Isao Teshirogi - Chairman, President, and CEO John Keller - Senior Vice President, R&D, Supervisory...

Shionogi & Co., Ltd. (SGIOY) Q1 2024 Earnings Call Transcript

July 29, 2024seekingalpha.com

Shionogi & Co., Ltd. (OTCPK:SGIOY) Q1 2024 Earnings Conference Call July 29, 2024 4:00 AM ET Company Participants Yoshimasa Kyokawa - Vice President, Corporate Communications Masako Kudou - Vice President of Finance & Accounting Department Kazuhiro Hatanaka - Senior Executive...

Shionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript

July 31, 2023seekingalpha.com

Shionogi & Co., Ltd. (OTCPK:SGIOF) Q1 2023 Earnings Conference Call July 31, 2023 5:15 AM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications John Keller - Senior Executive Officer, SVP, R&D Supervisory Unit Toshinobu Iwasaki - Senior Executive Officer,...

Shionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript

May 14, 2023seekingalpha.com

Shionogi & Co., Ltd. (OTCPK:SGIOF) Q1 2023 Earnings Conference Call May 10, 2023 10:00 PM ET Company Participants Yoshimasa Kyokawa - Investor Relations Isao Teshirogi - Chairman and CEO John Keller - Executive Officer, the General Manager of R&D and...